# Evaluation of Oral Modified-Release Tablets to Support the Approval of Additional Strengths

> **NIH FDA U01** · NORTHEASTERN UNIVERSITY · 2024 · $250,000

## Abstract

ABSTRACT
Oral modified-release (MR) drug products with modulated drug release characteristics (e.g., rate, duration, and
the site of drug release) have been widely used to achieve desired therapeutic effects, reduced adverse effects
and/or improved patient compliance than conventional oral solid dosage forms. More than half of the FDA
approved oral MR drug products are extended-release (ER) tablet products with multiple strengths. Until now,
appropriate factors to scale the formulation for additional strengths for oral MR tablets have yet to be determined.
Moreover, the key variables affecting drug release mechanism and formulation design spaces for different MR
technologies have not been fully understood and identified. The main objectives of this project are to: 1)
determine the impact of formulation variables (e.g., drug properties and excipients) on the drug release
mechanism of in-house made ER tablets based on quality-by-design (QbD) principles; 2) develop mechanistic
models parameterized with dissolution data obtained using comprehensive dissolution testing technologies to
compare the ER tablets and the corresponding reference drug products across multiple strengths to establish
dissolution safe spaces and to identify critical quality attributes (CQA’s); and 3) construct a “proof-of-concept”
machine learning model leveraging the database of complex oral MR drug products to identify key variables that
affect drug release mechanisms for different formulation design strategies. The proposed research builds upon
our extensive research on the formulation development, comparative product characterization, in vitro dissolution
testing as well as bioequivalence assessment and mechanistic modeling of complex oral MR solid dosage forms.
Biopharmaceutics classification system (BCS) Class I and Class II compounds ropinirole hydrochloride and
nifedipine will be studied as model drugs, respectively. ER tablets across multiple strengths with formulation and
process variables will be produced and comparatively characterized using the corresponding reference drug
products as controls. The drug release mechanism and in vitro dissolution profiles of the ER tablets across
multiple strengths will be characterized under different testing conditions including fasted and fed conditions with
simulated gastrointestinal motility. Moreover, mechanistic models (e.g., physiologically based pharmacokinetic
(PBPK), physiologically based biopharmaceutics models (PBBM)-PBPK) parameterized with the in vitro data
obtained will be developed to identify appropriate factors to scale the formulation for additional strengths for oral
MR tablets. Lastly, a comprehensive database of the approved oral MR drug products will be established, and
ML techniques will be employed to identify the key variables that impact drug release mechanism. The proposed
research will help advance the regulatory review and approval processes of oral MR tablet products, and support
the approval of additi...

## Key facts

- **NIH application ID:** 10918252
- **Project number:** 5U01FD007959-03
- **Recipient organization:** NORTHEASTERN UNIVERSITY
- **Principal Investigator:** Jie Shen
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** FDA
- **Fiscal year:** 2024
- **Award amount:** $250,000
- **Award type:** 5
- **Project period:** 2023-09-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10918252

## Citation

> US National Institutes of Health, RePORTER application 10918252, Evaluation of Oral Modified-Release Tablets to Support the Approval of Additional Strengths (5U01FD007959-03). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10918252. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*